London, UK, 29 May 2008 - Antisoma (LSE: ASM; USOTC:ATSMY) announces that it has received a milestone payment of USD 25 million from Novartis. This was triggered by the recent initiation of a phase III trial of ASA404 in non-small cell lung cancer.
Except for the historical information presented, certain matters discussed in this statement are forward looking statements that are subject to a number of risks and uncertainties that could cause actual results to differ materially from results, performance or achievements expressed or implied by such statements. These risks and uncertainties may be associated with product discovery and development, including statements regarding the company’s clinical development programmes, the expected timing of clinical trials and regulatory filings. Such statements are based on management’s current expectations, but actual results may differ materially.
Background on Antisoma
Headquartered in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates. Please visit www.antisoma.com for further information about Antisoma.
Copyright © Hugin AS 2008. All rights reserved.
Contact:
Source: Antisoma plc
